Compare Ishares Msci Brazil ETF (EWZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Neurocrine Biosciences Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.01 (market cap $11.30B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWZ | NBIX | |
|---|---|---|
Market Cap | $11.30B | $14.36B |
Volume | 44,036,597 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $185.50 |
52-Week Low | $28.79 | $123.10 |
Typical Hold Time | 50 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
